How to Value a Mid-Size DSO (10-30 Locations) in 2026

If you've built a dental service organization with 10-30 locations, you've crossed a threshold that fundamentally changes who wants to buy your business and what they'll pay. You're no longer a dentist selling a practice. You're a healthcare platform selling to private equity firms, large strategic DSOs, and institutional investors who think in terms of EBITDA multiples, management infrastructure, and growth trajectories. The valuations at this stage can be transformative — but only if you understand what buyers at this level actually underwrite.

I've worked on DSO transactions ranging from 5-location groups to 100+ location platforms, and the 10-30 location range is where the most value creation happens. You've proven you can scale past a handful of offices, but you haven't yet hit the size where growth naturally decelerates. That combination of proven execution and remaining runway is exactly what PE firms pay premium multiples for.

The Multiple Range: 10-18x EBITDA

Mid-size DSOs trade at 10-18x EBITDA, which is a remarkable range compared to individual dental practices that sell for 5-8x. That arbitrage — buying practices at 5-7x and building a platform that sells at 12-18x — is the entire economic engine of DSO consolidation. Understanding where in this range your group falls requires examining several interconnected factors.

At 10-12x EBITDA, you're looking at groups with 10-15 locations, concentrated in a single metro area, growing primarily through acquisition, with EBITDA margins of 15-20%, and some management infrastructure but still significant founder involvement in operations. This is a solid platform, but it hasn't fully de-risked.

At 14-18x EBITDA, the profile shifts materially: 20-30 locations across multiple markets, a mix of acquisition and de novo growth, EBITDA margins above 22%, a full central services team (CFO, COO, regional managers, HR), demonstrable same-store revenue growth, and a pipeline of identified acquisition targets or de novo sites. This is a business a PE firm can hand to a professional management team and scale to 50-100 locations.

Same-Store Growth: The Metric That Separates Good From Great

Every PE firm I've worked with on a DSO transaction asks the same question within the first 30 minutes: "What's your same-store growth?" They want to see revenue growth at locations that have been open for more than 12 months, isolated from the impact of new acquisitions or de novo openings.

Same-store growth above 5% annually signals a DSO that's actually making its practices better — better marketing, better patient retention, better case acceptance, better provider utilization. This is the strongest evidence a buyer can find that your central services infrastructure creates value rather than just extracting management fees.

Same-store growth below 2% (or negative) tells buyers that your existing locations are stagnant and all your growth comes from acquisitions. That's not necessarily fatal — some successful DSOs grow purely through M&A — but it caps your multiple because it suggests the platform doesn't meaningfully improve practice performance after acquisition.

The math is revealing. A 20-location DSO generating $40M revenue with 6% same-store growth is creating $2.4M in organic revenue annually. At 15x EBITDA on a 22% margin, that organic growth alone represents roughly $8M in enterprise value creation per year — before any acquisitions. Buyers will pay premium multiples for that kind of built-in growth engine.

De Novo Pipeline vs. Acquisition Growth

How you grow matters almost as much as how fast you grow. DSOs that can execute both acquisitions and de novo openings get higher multiples than those dependent on a single growth channel.

Acquisitions are the faster path. You buy an existing practice at 5-7x EBITDA, integrate it into your platform, improve margins through central services, and the value accretes immediately through the multiple arbitrage. But acquisition-only growth faces real constraints: purchase prices have risen as competition among DSO buyers intensifies, integration risk is real (I've seen DSOs stumble badly on their 15th or 20th integration), and the pipeline of willing sellers isn't infinite.

De novo openings are slower to reach maturity (typically 18-24 months to profitability) but cheaper on a per-location basis and more controllable. A DSO that has opened 5+ de novo locations successfully demonstrates a repeatable playbook that buyers view as a scalable growth asset. De novo capability is particularly valued because it signals operational sophistication — you know how to select sites, build out operatories, recruit providers, and ramp patient volume from zero.

A DSO with a documented pipeline of 5-10 identified acquisition targets plus 2-3 de novo sites in active development creates a compelling growth narrative that directly supports upper-range multiples.

Provider Count, Retention, and the Associate Model

The number and stability of your dentist workforce is the operational foundation of every DSO. Buyers scrutinize this relentlessly because provider retention directly determines revenue sustainability.

Provider-to-location ratio tells buyers about utilization and capacity. A 20-location DSO with 25 providers suggests some locations are single-provider offices with no backup coverage. A 20-location DSO with 40 providers suggests multi-provider offices with schedule density and built-in redundancy. Buyers prefer the latter because losing any single provider doesn't materially impact overall performance.

Associate retention rates above 85% annually are strong. Below 70%, buyers see a structural problem — likely compensation, culture, or management issues — that will persist post-acquisition. High turnover is expensive (recruiting and onboarding a new associate costs $50-100K in lost production and direct costs) and signals to patients that the practice is unstable.

Compensation structures matter in diligence. DSOs typically compensate associates on a percentage-of-collections model (25-35% of personal production). Buyers will benchmark your comp plans against market rates. If your associates are underpaid relative to market, buyers model compensation increases that reduce EBITDA. If overpaid, they question management discipline.

Central Services Infrastructure: The Platform Premium

The reason mid-size DSOs trade at 10-18x while individual practices trade at 5-8x is the infrastructure layer. Central services — the management team, systems, and processes that operate across all locations — is what buyers are actually paying the premium for.

At minimum, buyers expect to see: a dedicated CFO or finance function (not the founder doing books), revenue cycle management with central billing, HR and recruiting capability, marketing (both patient acquisition and provider recruiting), IT infrastructure (practice management software, ideally standardized across locations), and regional or area managers who oversee clusters of offices.

The key question buyers ask is: "If the founder left tomorrow, could this business continue to operate and grow?" If the answer is yes — because you have a COO running daily operations, regional managers handling practice performance, and a finance team managing cash flow — you have a platform worth premium multiples. If the founder is still making every meaningful decision, you have a large practice group, not a platform, and the multiple reflects that distinction.

EBITDA Adjustments and Quality of Earnings

At this transaction size, every buyer will require a quality of earnings analysis performed by an independent accounting firm. The QofE process will scrutinize every EBITDA add-back and adjustment, and I've seen $2-5M of "adjusted EBITDA" evaporate during QofE at mid-size DSOs.

Common areas where DSO EBITDA adjustments get challenged: management fees charged to individual practices (buyers want to see these at market rates), personal expenses run through the business, one-time integration costs that recur every time you acquire a new practice (making them not actually one-time), and lab costs or supply purchasing that hasn't been optimized despite claims of group purchasing power.

Get your QofE done proactively — before going to market. A sell-side QofE costs $75-150K but prevents surprises during buyer diligence that can derail a transaction or trigger re-trades on price.

The Bottom Line

A mid-size DSO with 10-30 locations is a serious asset that attracts serious capital. The 10-18x EBITDA range is real, but where you fall within it is determined by factors you can influence: same-store growth, de novo execution capability, provider retention, management depth, and clean financials. The DSOs I've seen exit at the top of the range share a common thread — their founders spent 2-3 years building infrastructure and proving growth before going to market. They didn't just build a collection of dental practices. They built a business that runs, grows, and creates value independent of any single person. That's what PE firms pay 15-18x for.